CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with ...
(NASDAQ: GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to ...
Modern wireless communication systems prefer higher frequencies to meet the growing demand for faster data transfer. The ...
Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...
A deep reinforcement learning framework optimizes silicon-based photonic crystal fiber modulators, achieving ultra-low ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...
It's built like a tank and sounds the bomb ...